Who We Are

Zymeworks is a global biotechnology company developing novel, multifunctional therapeutics to address difficult-to-treat cancers and other serious diseases.

We are driven by our mission to make a meaningful difference for people around the world who are impacted by difficult-to-treat cancers and other serious diseases. Our complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics.

Zymeworks is advancing a deep pipeline of product candidates based on our experience and capabilities in both antibody-drug conjugates and multispecific antibodies.

In addition to Zymeworks’ wholly owned pipeline, its therapeutic platforms have been further leveraged and validated in product development through strategic partnerships with global biopharmaceutical companies.

Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody developed using Zymeworks proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene and Jazz Pharmaceuticals, granting each with exclusive rights to develop and commercialize zanidatamab across the globe. Zanidatamab is currently being evaluated in global Phase 1, Phase 2, and pivotal clinical trials as a best-in-class treatment for patients with HER2-expressing cancers, including biliary tract, gastroesophageal adenocarcinomas, breast, and other HER2-expressing tumor types.

Zymeworks’ next clinical candidate, zanidatamab zovodotin, is a HER2-targeted bispecific antibody drug conjugate developed using Zymeworks’ proprietary Azymetric™ and ZymeLink™ Auristatin technologies. Zanidatamab zovodotin is currently being evaluated in a Phase 1 clinical trial as a treatment for patients with a variety of HER2-expressing cancers.

Leadership Team

Kenneth Galbraith

Chair & CEO

Mr. Galbraith has served as Zymeworks’ Chair & CEO since January 2022. Mr. Galbraith has over 35 years’ experience in biotechnology and venture capital having acted as an executive, director, investor as well as an advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors across North America and the UK in the growth of both private and public companies from an early-stage through regulatory approval and commercialization. Ken has worked with many biotechnology companies including: Macrogenics, AnorMED, Alder Pharmaceuticals, Celator Pharmaceuticals, Novadaq, Profound Medical, Fairhaven Pharmaceuticals, Tekmira, Angiotech, Aquinox, and Xenon Pharmaceuticals among others. Mr. Galbraith currently serves on the board of directors of Profound Medical and Kalium Health. He earned a Bachelor of Commerce (Honors) degree from the University of British Columbia in 1985.

Kenneth Galbraith

Chair & CEO

Mr. Galbraith has served as Zymeworks’ Chair & CEO since January 2022. Mr. Galbraith has over 35 years’ experience in biotechnology and venture capital having acted as an executive, director, investor as well as an advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors across North America and the UK in the growth of both private and public companies from an early-stage through regulatory approval and commercialization. Ken has worked with many biotechnology companies including: Macrogenics, AnorMED, Alder Pharmaceuticals, Celator Pharmaceuticals, Novadaq, Profound Medical, Fairhaven Pharmaceuticals, Tekmira, Angiotech, Aquinox, and Xenon Pharmaceuticals among others. Mr. Galbraith currently serves on the board of directors of Profound Medical and Kalium Health. He earned a Bachelor of Commerce (Honors) degree from the University of British Columbia in 1985.

Kenneth Galbraith

Chair & CEO

Mr. Galbraith has served as Zymeworks’ Chair & CEO since January 2022. Mr. Galbraith has over 35 years’ experience in biotechnology and venture capital having acted as an executive, director, investor as well as an advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors across North America and the UK in the growth of both private and public companies from an early-stage through regulatory approval and commercialization. Ken has worked with many biotechnology companies including: Macrogenics, AnorMED, Alder Pharmaceuticals, Celator Pharmaceuticals, Novadaq, Profound Medical, Fairhaven Pharmaceuticals, Tekmira, Angiotech, Aquinox, and Xenon Pharmaceuticals among others. Mr. Galbraith currently serves on the board of directors of Profound Medical and Kalium Health. He earned a Bachelor of Commerce (Honors) degree from the University of British Columbia in 1985.

Paul Moore

PhD

Chief Scientific Officer

Dr. Moore joined Zymeworks in July 2022 and currently serves as our Chief Scientific Officer. Dr. Moore brings over 25 years of US-based experience in biologics drug discovery and development in biotechnology research. His career efforts have led to the discovery and development of a range of FDA-approved and clinical-stage biologics for patients with difficult-to-treat cancers and autoimmune conditions. Prior to joining Zymeworks, Paul served as Vice President, Cell Biology, and Immunology at MacroGenics, where he worked on the development of numerous clinical stage compounds and scientific collaborations with a range of pharmaceutical partners, including Pfizer, Servier, Gilead, Takeda, Janssen, Roche and Zai Labs. Prior to joining MacroGenics, he was Director of Cell Biology at Celera where he oversaw research efforts to develop novel antibody-based therapeutics. Dr. Moore received a Ph.D. in molecular genetics from the University of Glasgow. He has an extensive research record co-authoring over 75 peer-reviewed manuscripts and is a named co-inventor on over 50 issued US patents.

Paul Moore

PhD

Chief Scientific Officer

Dr. Moore joined Zymeworks in July 2022 and currently serves as our Chief Scientific Officer. Dr. Moore brings over 25 years of US-based experience in biologics drug discovery and development in biotechnology research. His career efforts have led to the discovery and development of a range of FDA-approved and clinical-stage biologics for patients with difficult-to-treat cancers and autoimmune conditions. Prior to joining Zymeworks, Paul served as Vice President, Cell Biology, and Immunology at MacroGenics, where he worked on the development of numerous clinical stage compounds and scientific collaborations with a range of pharmaceutical partners, including Pfizer, Servier, Gilead, Takeda, Janssen, Roche and Zai Labs. Prior to joining MacroGenics, he was Director of Cell Biology at Celera where he oversaw research efforts to develop novel antibody-based therapeutics. Dr. Moore received a Ph.D. in molecular genetics from the University of Glasgow. He has an extensive research record co-authoring over 75 peer-reviewed manuscripts and is a named co-inventor on over 50 issued US patents.

PhD

Paul Moore

PhD

Chief Scientific Officer

Dr. Moore joined Zymeworks in July 2022 and currently serves as our Chief Scientific Officer. Dr. Moore brings over 25 years of US-based experience in biologics drug discovery and development in biotechnology research. His career efforts have led to the discovery and development of a range of FDA-approved and clinical-stage biologics for patients with difficult-to-treat cancers and autoimmune conditions. Prior to joining Zymeworks, Paul served as Vice President, Cell Biology, and Immunology at MacroGenics, where he worked on the development of numerous clinical stage compounds and scientific collaborations with a range of pharmaceutical partners, including Pfizer, Servier, Gilead, Takeda, Janssen, Roche and Zai Labs. Prior to joining MacroGenics, he was Director of Cell Biology at Celera where he oversaw research efforts to develop novel antibody-based therapeutics. Dr. Moore received a Ph.D. in molecular genetics from the University of Glasgow. He has an extensive research record co-authoring over 75 peer-reviewed manuscripts and is a named co-inventor on over 50 issued US patents.

Daniel Dex

JD

Senior Vice President, Corporate Secretary and General Counsel

Mr. Dex joined Zymeworks in September 2017, and currently serves as our Senior Vice President, Corporate Secretary and General Counsel. Mr. Dex brings over 25 years of diverse legal experience to Zymeworks, having worked in private practice at prominent law firms in both the U.S. and Canada, in-house with Avigilon Corporation (a Motorola Solutions company) and the New York Public Library, and with the U.S. federal district court for the Eastern District of Pennsylvania. Mr. Dex received a J.D. from the University of Pennsylvania Law School and a B.A. from Brown University. He is a member of the bars of both New York and British Columbia.

Daniel Dex

JD

Senior Vice President, Corporate Secretary and General Counsel

Mr. Dex joined Zymeworks in September 2017, and currently serves as our Senior Vice President, Corporate Secretary and General Counsel. Mr. Dex brings over 25 years of diverse legal experience to Zymeworks, having worked in private practice at prominent law firms in both the U.S. and Canada, in-house with Avigilon Corporation (a Motorola Solutions company) and the New York Public Library, and with the U.S. federal district court for the Eastern District of Pennsylvania. Mr. Dex received a J.D. from the University of Pennsylvania Law School and a B.A. from Brown University. He is a member of the bars of both New York and British Columbia.

JD

Daniel Dex

JD

Senior Vice President, Corporate Secretary and General Counsel

Mr. Dex joined Zymeworks in September 2017, and currently serves as our Senior Vice President, Corporate Secretary and General Counsel. Mr. Dex brings over 25 years of diverse legal experience to Zymeworks, having worked in private practice at prominent law firms in both the U.S. and Canada, in-house with Avigilon Corporation (a Motorola Solutions company) and the New York Public Library, and with the U.S. federal district court for the Eastern District of Pennsylvania. Mr. Dex received a J.D. from the University of Pennsylvania Law School and a B.A. from Brown University. He is a member of the bars of both New York and British Columbia.

Jeffrey Smith

MD, FRCP

Senior Vice President, Early-Stage Development

Dr. Smith joined Zymeworks in January 2023 and currently serves as our Senior Vice President of Early-Stage Development based at our European hub in Dublin, Ireland. Dr. Smith has held many senior positions within the pharmaceutical industry, most recently, Managing Director of Alder Biopharmaceuticals Inc. Dublin, Ireland and before that Senior Vice President, Translational Medicine at Alder Biopharmaceuticals Inc, Seattle. Dr. Smith was responsible for the clinical development (phase I – III) of eptinezumab (anti-CGRP antibody for migraine) and clazakizumab (anti -IL-6 antibody for rheumatoid arthritis and cancer cachexia). Dr. Smith was also a founder of Alder Biopharmaceutcials Inc (founded 2004). Dr. Smith received his MB BS and MD from the University of London, UK.

Jeffrey Smith

MD, FRCP

Senior Vice President, Early-Stage Development

Dr. Smith joined Zymeworks in January 2023 and currently serves as our Senior Vice President of Early-Stage Development based at our European hub in Dublin, Ireland. Dr. Smith has held many senior positions within the pharmaceutical industry, most recently, Managing Director of Alder Biopharmaceuticals Inc. Dublin, Ireland and before that Senior Vice President, Translational Medicine at Alder Biopharmaceuticals Inc, Seattle. Dr. Smith was responsible for the clinical development (phase I – III) of eptinezumab (anti-CGRP antibody for migraine) and clazakizumab (anti -IL-6 antibody for rheumatoid arthritis and cancer cachexia). Dr. Smith was also a founder of Alder Biopharmaceutcials Inc (founded 2004). Dr. Smith received his MB BS and MD from the University of London, UK.

MD, FRCP

Jeffrey Smith

MD, FRCP

Senior Vice President, Early-Stage Development

Dr. Smith joined Zymeworks in January 2023 and currently serves as our Senior Vice President of Early-Stage Development based at our European hub in Dublin, Ireland. Dr. Smith has held many senior positions within the pharmaceutical industry, most recently, Managing Director of Alder Biopharmaceuticals Inc. Dublin, Ireland and before that Senior Vice President, Translational Medicine at Alder Biopharmaceuticals Inc, Seattle. Dr. Smith was responsible for the clinical development (phase I – III) of eptinezumab (anti-CGRP antibody for migraine) and clazakizumab (anti -IL-6 antibody for rheumatoid arthritis and cancer cachexia). Dr. Smith was also a founder of Alder Biopharmaceutcials Inc (founded 2004). Dr. Smith received his MB BS and MD from the University of London, UK.

Chris Astle

PhD

Senior Vice President & Chief Financial Officer

Dr. Astle joined Zymeworks in April 2021 and currently serves as Senior Vice President and Chief Financial Officer. Prior to joining Zymeworks, Dr. Astle worked as a Chief Financial Officer at the CFO Centre in British Columbia, Canada from March 2020 to March 2021, and as Vice President, Finance at Alder BioPharmaceuticals Inc. in Seattle, Washington from April 2019 to February 2020. From August 2017 to January 2020, he served as Chief Executive Officer and founder of Think Forwards, a boutique financial consulting firm in London, UK. Dr. Astle worked at Allergan from 2011 to 2017, including as the Associate Vice President Finance, International Division from July 2016 to July 2017, managing multiple product launches, M&A transactions and restructurings, with a team of 170 across 60 countries. He is a UK Chartered Accountant (ICAS), qualifying at PwC London, UK in Audit & Pharmaceutical Performance Improvement Consulting with audit clients including GSK. Dr. Astle serves as a member of the board of directors of two private biotechnology companies, Oak Bay Biosciences (2020-present) and Healome Therapeutics (2021-present). During his time in the UK, he was the Chair of the 2018 CFO Agenda conference, guest lecturer at the Henley Business School, and judge at the British Accountancy Awards. Dr. Astle holds a PhD in Organic Chemistry from the University of Bristol (UK) and a MChem in Chemistry from the University of Liverpool (UK) and is also a certified ski instructor.

Chris Astle

PhD

Senior Vice President & Chief Financial Officer

Dr. Astle joined Zymeworks in April 2021 and currently serves as Senior Vice President and Chief Financial Officer. Prior to joining Zymeworks, Dr. Astle worked as a Chief Financial Officer at the CFO Centre in British Columbia, Canada from March 2020 to March 2021, and as Vice President, Finance at Alder BioPharmaceuticals Inc. in Seattle, Washington from April 2019 to February 2020. From August 2017 to January 2020, he served as Chief Executive Officer and founder of Think Forwards, a boutique financial consulting firm in London, UK. Dr. Astle worked at Allergan from 2011 to 2017, including as the Associate Vice President Finance, International Division from July 2016 to July 2017, managing multiple product launches, M&A transactions and restructurings, with a team of 170 across 60 countries. He is a UK Chartered Accountant (ICAS), qualifying at PwC London, UK in Audit & Pharmaceutical Performance Improvement Consulting with audit clients including GSK. Dr. Astle serves as a member of the board of directors of two private biotechnology companies, Oak Bay Biosciences (2020-present) and Healome Therapeutics (2021-present). During his time in the UK, he was the Chair of the 2018 CFO Agenda conference, guest lecturer at the Henley Business School, and judge at the British Accountancy Awards. Dr. Astle holds a PhD in Organic Chemistry from the University of Bristol (UK) and a MChem in Chemistry from the University of Liverpool (UK) and is also a certified ski instructor.

PhD

Chris Astle

PhD

Senior Vice President & Chief Financial Officer

Dr. Astle joined Zymeworks in April 2021 and currently serves as Senior Vice President and Chief Financial Officer. Prior to joining Zymeworks, Dr. Astle worked as a Chief Financial Officer at the CFO Centre in British Columbia, Canada from March 2020 to March 2021, and as Vice President, Finance at Alder BioPharmaceuticals Inc. in Seattle, Washington from April 2019 to February 2020. From August 2017 to January 2020, he served as Chief Executive Officer and founder of Think Forwards, a boutique financial consulting firm in London, UK. Dr. Astle worked at Allergan from 2011 to 2017, including as the Associate Vice President Finance, International Division from July 2016 to July 2017, managing multiple product launches, M&A transactions and restructurings, with a team of 170 across 60 countries. He is a UK Chartered Accountant (ICAS), qualifying at PwC London, UK in Audit & Pharmaceutical Performance Improvement Consulting with audit clients including GSK. Dr. Astle serves as a member of the board of directors of two private biotechnology companies, Oak Bay Biosciences (2020-present) and Healome Therapeutics (2021-present). During his time in the UK, he was the Chair of the 2018 CFO Agenda conference, guest lecturer at the Henley Business School, and judge at the British Accountancy Awards. Dr. Astle holds a PhD in Organic Chemistry from the University of Bristol (UK) and a MChem in Chemistry from the University of Liverpool (UK) and is also a certified ski instructor.

Mark Hollywood

Executive Vice President and Head of Technical and Manufacturing Operations

Mr. Hollywood joined Zymeworks in 2019 and currently serves as our Executive Vice President and Head of Technical and Manufacturing Operations. Mr. Hollywood brings over 25 years of experience in the biopharmaceutical industry, most recently as Vice President and Head of ZymoGenetics (a Bristol-Myers Squibb company), where he oversaw biologics development, manufacturing, quality, and supply chain operations. He joined ZymoGenetics in 2010 and led technical operations for a portfolio of clinical and commercial products, and was responsible for building and managing a multi-host drug substance manufacturing facility. Mr. Hollywood brings a wealth of experience in operations management, having held positions of increasing responsibility in process science, manufacturing, quality, and regulatory compliance at organizations including Amgen, Dendreon and Centeon (a Rhone-Poulenc Rorer and Hoescht company). Mr. Hollywood has a Bachelor of Science degree in Biological Sciences from Western Illinois University.

Mark Hollywood

Executive Vice President and Head of Technical and Manufacturing Operations

Mr. Hollywood joined Zymeworks in 2019 and currently serves as our Executive Vice President and Head of Technical and Manufacturing Operations. Mr. Hollywood brings over 25 years of experience in the biopharmaceutical industry, most recently as Vice President and Head of ZymoGenetics (a Bristol-Myers Squibb company), where he oversaw biologics development, manufacturing, quality, and supply chain operations. He joined ZymoGenetics in 2010 and led technical operations for a portfolio of clinical and commercial products, and was responsible for building and managing a multi-host drug substance manufacturing facility. Mr. Hollywood brings a wealth of experience in operations management, having held positions of increasing responsibility in process science, manufacturing, quality, and regulatory compliance at organizations including Amgen, Dendreon and Centeon (a Rhone-Poulenc Rorer and Hoescht company). Mr. Hollywood has a Bachelor of Science degree in Biological Sciences from Western Illinois University.

Mark Hollywood

Executive Vice President and Head of Technical and Manufacturing Operations

Mr. Hollywood joined Zymeworks in 2019 and currently serves as our Executive Vice President and Head of Technical and Manufacturing Operations. Mr. Hollywood brings over 25 years of experience in the biopharmaceutical industry, most recently as Vice President and Head of ZymoGenetics (a Bristol-Myers Squibb company), where he oversaw biologics development, manufacturing, quality, and supply chain operations. He joined ZymoGenetics in 2010 and led technical operations for a portfolio of clinical and commercial products, and was responsible for building and managing a multi-host drug substance manufacturing facility. Mr. Hollywood brings a wealth of experience in operations management, having held positions of increasing responsibility in process science, manufacturing, quality, and regulatory compliance at organizations including Amgen, Dendreon and Centeon (a Rhone-Poulenc Rorer and Hoescht company). Mr. Hollywood has a Bachelor of Science degree in Biological Sciences from Western Illinois University.

John Fann

PhD

Vice President, Technical Operations Process Science in Technical & Manufacturing Operations

Dr. Fann joins Zymeworks with over 20 years of experience in bioprocess development and biologics manufacturing and controls. Dr. Fann started his postdoctoral career with StemCell Technologies in Vancouver, then joined Seattle Genetics in its early years. After establishing the upstream function and accomplishing the first technology transfer and clinical manufacturing for Seagen, Dr. Fann joined AbbVie Bioresearch Center. He held several leadership positions in Process Sciences and MS&T. At AbbVie, Dr. Fann experienced many clinical projects and helped to launch and scale up several commercial biotherapeutics, including the blockbuster drug Humira. Dr. Fann joined Bristol Myers Squib after returning to Seattle, as the head of M&ST and Bioprocess Development. He was leading microbial process development at BMS and accomplished several early and late-stage clinical projects. Prior to Zymeworks, Dr. Fann was VP of Bioprocess R&D at AGC Biologics, leading the global new technology development at AGC. Dr. Fann holds a Ph.D. in Chemical Engineering from the University of British Columbia.

John Fann

PhD

Vice President, Technical Operations Process Science in Technical & Manufacturing Operations

Dr. Fann joins Zymeworks with over 20 years of experience in bioprocess development and biologics manufacturing and controls. Dr. Fann started his postdoctoral career with StemCell Technologies in Vancouver, then joined Seattle Genetics in its early years. After establishing the upstream function and accomplishing the first technology transfer and clinical manufacturing for Seagen, Dr. Fann joined AbbVie Bioresearch Center. He held several leadership positions in Process Sciences and MS&T. At AbbVie, Dr. Fann experienced many clinical projects and helped to launch and scale up several commercial biotherapeutics, including the blockbuster drug Humira. Dr. Fann joined Bristol Myers Squib after returning to Seattle, as the head of M&ST and Bioprocess Development. He was leading microbial process development at BMS and accomplished several early and late-stage clinical projects. Prior to Zymeworks, Dr. Fann was VP of Bioprocess R&D at AGC Biologics, leading the global new technology development at AGC. Dr. Fann holds a Ph.D. in Chemical Engineering from the University of British Columbia.

PhD

John Fann

PhD

Vice President, Technical Operations Process Science in Technical & Manufacturing Operations

Dr. Fann joins Zymeworks with over 20 years of experience in bioprocess development and biologics manufacturing and controls. Dr. Fann started his postdoctoral career with StemCell Technologies in Vancouver, then joined Seattle Genetics in its early years. After establishing the upstream function and accomplishing the first technology transfer and clinical manufacturing for Seagen, Dr. Fann joined AbbVie Bioresearch Center. He held several leadership positions in Process Sciences and MS&T. At AbbVie, Dr. Fann experienced many clinical projects and helped to launch and scale up several commercial biotherapeutics, including the blockbuster drug Humira. Dr. Fann joined Bristol Myers Squib after returning to Seattle, as the head of M&ST and Bioprocess Development. He was leading microbial process development at BMS and accomplished several early and late-stage clinical projects. Prior to Zymeworks, Dr. Fann was VP of Bioprocess R&D at AGC Biologics, leading the global new technology development at AGC. Dr. Fann holds a Ph.D. in Chemical Engineering from the University of British Columbia.

Raquera Brown

Executive Director, Quality

Ms. Brown joined Zymeworks in September 2022 and serves as our Executive Director, Quality. Ms. Brown brings over 25 years of experience in the pharmaceutical and biotechnology industries. Prior to joining Zymeworks, Ms. Brown served as Senior Director/Head of Quality Sio Gene Therapies. She has held roles of increasing leadership responsibility in Research and Development, Quality Control, GMP Quality, Compliance, Clinical and Nonclinical QA working across multiple dosage forms, therapeutic areas, and lifecycle phases at organizations including Merck, Novartis, Schering-Plough, and Endo Pharmaceuticals.  Ms. Brown received a Bachelor of Science degree in Biological Sciences from Rutgers University.

Raquera Brown

Executive Director, Quality

Ms. Brown joined Zymeworks in September 2022 and serves as our Executive Director, Quality. Ms. Brown brings over 25 years of experience in the pharmaceutical and biotechnology industries. Prior to joining Zymeworks, Ms. Brown served as Senior Director/Head of Quality Sio Gene Therapies. She has held roles of increasing leadership responsibility in Research and Development, Quality Control, GMP Quality, Compliance, Clinical and Nonclinical QA working across multiple dosage forms, therapeutic areas, and lifecycle phases at organizations including Merck, Novartis, Schering-Plough, and Endo Pharmaceuticals.  Ms. Brown received a Bachelor of Science degree in Biological Sciences from Rutgers University.

Raquera Brown

Executive Director, Quality

Ms. Brown joined Zymeworks in September 2022 and serves as our Executive Director, Quality. Ms. Brown brings over 25 years of experience in the pharmaceutical and biotechnology industries. Prior to joining Zymeworks, Ms. Brown served as Senior Director/Head of Quality Sio Gene Therapies. She has held roles of increasing leadership responsibility in Research and Development, Quality Control, GMP Quality, Compliance, Clinical and Nonclinical QA working across multiple dosage forms, therapeutic areas, and lifecycle phases at organizations including Merck, Novartis, Schering-Plough, and Endo Pharmaceuticals.  Ms. Brown received a Bachelor of Science degree in Biological Sciences from Rutgers University.

Bijal Desai

MBA

Executive Director, Corporate Finance, FP&A and Procurement

Ms. Desai joined Zymeworks in May 2020 and currently serves as the Executive Director of Corporate Finance, FP&A and Procurement. Ms. Desai brings 17 years of experience providing oversight of operational and strategic finance support in the customer service, technology, and life sciences industries. Prior to joining Zymeworks, Ms. Desai held a variety of R&D and Commercial FP&A and Corporate Strategy positions, starting with CTI BioPharma, Juno Therapeutics, and Alder BioPharmaceutical Inc. Ms. Desai holds her MBA with a concentration in Finance from Texas A&M University, and is an active member of Healthcare Businesswomen’s Association (HBA) Seattle Chapter holding the position of Mentoring Chair.

Bijal Desai

MBA

Executive Director, Corporate Finance, FP&A and Procurement

Ms. Desai joined Zymeworks in May 2020 and currently serves as the Executive Director of Corporate Finance, FP&A and Procurement. Ms. Desai brings 17 years of experience providing oversight of operational and strategic finance support in the customer service, technology, and life sciences industries. Prior to joining Zymeworks, Ms. Desai held a variety of R&D and Commercial FP&A and Corporate Strategy positions, starting with CTI BioPharma, Juno Therapeutics, and Alder BioPharmaceutical Inc. Ms. Desai holds her MBA with a concentration in Finance from Texas A&M University, and is an active member of Healthcare Businesswomen’s Association (HBA) Seattle Chapter holding the position of Mentoring Chair.

MBA

Bijal Desai

MBA

Executive Director, Corporate Finance, FP&A and Procurement

Ms. Desai joined Zymeworks in May 2020 and currently serves as the Executive Director of Corporate Finance, FP&A and Procurement. Ms. Desai brings 17 years of experience providing oversight of operational and strategic finance support in the customer service, technology, and life sciences industries. Prior to joining Zymeworks, Ms. Desai held a variety of R&D and Commercial FP&A and Corporate Strategy positions, starting with CTI BioPharma, Juno Therapeutics, and Alder BioPharmaceutical Inc. Ms. Desai holds her MBA with a concentration in Finance from Texas A&M University, and is an active member of Healthcare Businesswomen’s Association (HBA) Seattle Chapter holding the position of Mentoring Chair.

Lucas Donigian

MBA

Executive Director, Business Development

Mr. Donigian joined the Business Development group at Zymeworks in March 2020 and has been serving as Executive Director of Business Development since February 2023. Mr. Donigian has over 15 years in the biotechnology and biopharma industry across drug development and diagnostics. Prior to joining Zymeworks, Mr. Donigian was the Director of Business Development and BioPharma collaborations at NanoString Technologies, where he lead diagnostics business development efforts. Prior to that, Mr. Donigian was a Corporate Development consultant with Dendreon where he facilitated buy and sell side M&A analysis for late-stage opportunities. Mr. Donigian started his career developing novel cancer stem cell therapeutics at OncoMed Pharmaceuticals helping to bring multiple therapeutic candidates into first in human trials. Mr. Donigian received his Molecular Biology and Organic Chemistry from San Jose State University and an MBA from the University of Washington.

Lucas Donigian

MBA

Executive Director, Business Development

Mr. Donigian joined the Business Development group at Zymeworks in March 2020 and has been serving as Executive Director of Business Development since February 2023. Mr. Donigian has over 15 years in the biotechnology and biopharma industry across drug development and diagnostics. Prior to joining Zymeworks, Mr. Donigian was the Director of Business Development and BioPharma collaborations at NanoString Technologies, where he lead diagnostics business development efforts. Prior to that, Mr. Donigian was a Corporate Development consultant with Dendreon where he facilitated buy and sell side M&A analysis for late-stage opportunities. Mr. Donigian started his career developing novel cancer stem cell therapeutics at OncoMed Pharmaceuticals helping to bring multiple therapeutic candidates into first in human trials. Mr. Donigian received his Molecular Biology and Organic Chemistry from San Jose State University and an MBA from the University of Washington.

MBA

Lucas Donigian

MBA

Executive Director, Business Development

Mr. Donigian joined the Business Development group at Zymeworks in March 2020 and has been serving as Executive Director of Business Development since February 2023. Mr. Donigian has over 15 years in the biotechnology and biopharma industry across drug development and diagnostics. Prior to joining Zymeworks, Mr. Donigian was the Director of Business Development and BioPharma collaborations at NanoString Technologies, where he lead diagnostics business development efforts. Prior to that, Mr. Donigian was a Corporate Development consultant with Dendreon where he facilitated buy and sell side M&A analysis for late-stage opportunities. Mr. Donigian started his career developing novel cancer stem cell therapeutics at OncoMed Pharmaceuticals helping to bring multiple therapeutic candidates into first in human trials. Mr. Donigian received his Molecular Biology and Organic Chemistry from San Jose State University and an MBA from the University of Washington.

Cathie Graham

JD

Executive Director, Legal

Ms. Graham joined Zymeworks in September 2018, and currently serves as our Executive Director, Legal. Ms. Graham brings over 17 years of diverse legal experience to Zymeworks, having previously worked in private practice for over a decade at one of Canada’s largest law firms, and in-house with Avigilon Corporation (a Motorola Solutions company). Ms. Graham received a LL.B/J.D. from Queen’s University and a Bachelor of Arts from Concordia University. She is a member of the bar in British Columbia.

Cathie Graham

JD

Executive Director, Legal

Ms. Graham joined Zymeworks in September 2018, and currently serves as our Executive Director, Legal. Ms. Graham brings over 17 years of diverse legal experience to Zymeworks, having previously worked in private practice for over a decade at one of Canada’s largest law firms, and in-house with Avigilon Corporation (a Motorola Solutions company). Ms. Graham received a LL.B/J.D. from Queen’s University and a Bachelor of Arts from Concordia University. She is a member of the bar in British Columbia.

JD

Cathie Graham

JD

Executive Director, Legal

Ms. Graham joined Zymeworks in September 2018, and currently serves as our Executive Director, Legal. Ms. Graham brings over 17 years of diverse legal experience to Zymeworks, having previously worked in private practice for over a decade at one of Canada’s largest law firms, and in-house with Avigilon Corporation (a Motorola Solutions company). Ms. Graham received a LL.B/J.D. from Queen’s University and a Bachelor of Arts from Concordia University. She is a member of the bar in British Columbia.

Laura O’Connor

Executive Director and Head of Global Human Resources

Ms. O’Connor joined Zymeworks in 2020 and currently serves as our Executive Director and Head of Global Human Resources. Ms. O’Connor brings over 20 years of experience within Human Resources, specializing in the pharmaceutical and biotech industry for over 13 years. Prior to joining Zymeworks, Ms. O’Connor held a variety of Human Resources leadership positions, starting with PointClickCare, Takeda Canada, Ferring Pharmaceuticals and most recently Merz Pharma. Ms. O’Connor holds a Bachelor of Arts degree in Psychology from the University of Waterloo and a certificate in Strategic Human Resources Management from the Rotman School of Business.

Laura O’Connor

Executive Director and Head of Global Human Resources

Ms. O’Connor joined Zymeworks in 2020 and currently serves as our Executive Director and Head of Global Human Resources. Ms. O’Connor brings over 20 years of experience within Human Resources, specializing in the pharmaceutical and biotech industry for over 13 years. Prior to joining Zymeworks, Ms. O’Connor held a variety of Human Resources leadership positions, starting with PointClickCare, Takeda Canada, Ferring Pharmaceuticals and most recently Merz Pharma. Ms. O’Connor holds a Bachelor of Arts degree in Psychology from the University of Waterloo and a certificate in Strategic Human Resources Management from the Rotman School of Business.

Laura O’Connor

Executive Director and Head of Global Human Resources

Ms. O’Connor joined Zymeworks in 2020 and currently serves as our Executive Director and Head of Global Human Resources. Ms. O’Connor brings over 20 years of experience within Human Resources, specializing in the pharmaceutical and biotech industry for over 13 years. Prior to joining Zymeworks, Ms. O’Connor held a variety of Human Resources leadership positions, starting with PointClickCare, Takeda Canada, Ferring Pharmaceuticals and most recently Merz Pharma. Ms. O’Connor holds a Bachelor of Arts degree in Psychology from the University of Waterloo and a certificate in Strategic Human Resources Management from the Rotman School of Business.

Joe Woolery

PharmD, BCOP

Executive Director, Early-Stage Development

Dr. Woolery joined Zymeworks in September 2019 and currently serves as our Executive Director of Early-Stage Development in the Americas and Global Lead for zanidatamab zovodotin (ZW49). Dr. Woolery previously held positions at Seagen working on registrational studies with Adcetris in Peripheral T-Cell Lymphoma and Tukysa in HER2+ Metastatic Breast Cancer. Prior to transitioning to the pharmaceutical industry, Dr. Woolery practiced as a Clinical Oncology Pharmacist at the University of Texas M.D. Anderson and Banner M.D. Anderson Cancer Centers. Dr. Woolery received a PharmD from the University of Missouri-Kansas City. He also completed residency’s in clinical pharmacy practice at The University of Arizona and oncology fellowship at H. Lee Moffitt Cancer Center and Research Institute. Dr. Woolery is a board certified oncology pharmacist and a member of the American Society of Clinical Oncology and the European Society of Medical Oncology.

Joe Woolery

PharmD, BCOP

Executive Director, Early-Stage Development

Dr. Woolery joined Zymeworks in September 2019 and currently serves as our Executive Director of Early-Stage Development in the Americas and Global Lead for zanidatamab zovodotin (ZW49). Dr. Woolery previously held positions at Seagen working on registrational studies with Adcetris in Peripheral T-Cell Lymphoma and Tukysa in HER2+ Metastatic Breast Cancer. Prior to transitioning to the pharmaceutical industry, Dr. Woolery practiced as a Clinical Oncology Pharmacist at the University of Texas M.D. Anderson and Banner M.D. Anderson Cancer Centers. Dr. Woolery received a PharmD from the University of Missouri-Kansas City. He also completed residency’s in clinical pharmacy practice at The University of Arizona and oncology fellowship at H. Lee Moffitt Cancer Center and Research Institute. Dr. Woolery is a board certified oncology pharmacist and a member of the American Society of Clinical Oncology and the European Society of Medical Oncology.

PharmD, BCOP

Joe Woolery

PharmD, BCOP

Executive Director, Early-Stage Development

Dr. Woolery joined Zymeworks in September 2019 and currently serves as our Executive Director of Early-Stage Development in the Americas and Global Lead for zanidatamab zovodotin (ZW49). Dr. Woolery previously held positions at Seagen working on registrational studies with Adcetris in Peripheral T-Cell Lymphoma and Tukysa in HER2+ Metastatic Breast Cancer. Prior to transitioning to the pharmaceutical industry, Dr. Woolery practiced as a Clinical Oncology Pharmacist at the University of Texas M.D. Anderson and Banner M.D. Anderson Cancer Centers. Dr. Woolery received a PharmD from the University of Missouri-Kansas City. He also completed residency’s in clinical pharmacy practice at The University of Arizona and oncology fellowship at H. Lee Moffitt Cancer Center and Research Institute. Dr. Woolery is a board certified oncology pharmacist and a member of the American Society of Clinical Oncology and the European Society of Medical Oncology.

Josemund Menezes

MBBS, BCMAS

Managing Director, Early-Stage Development (Asia Pacific)

Dr. Menezes has over 18 years of industry experience across MNC Pharma, biotech and CRO, spearheading global clinical development (Phase I to III executional strategy) in Oncology, Vaccines, and Immunology therapy areas. Prior to joining Zymeworks, Dr. Menezes held cross-functional team management and leadership roles at ASLAN Pharmaceuticals, Tessa Therapeutics, and Sanofi Pasteur. Dr. Menezes graduated from Maharashtra University of Health Sciences, India with a Bachelor of Medicine and Bachelor of Surgery (MBBS) degree, followed by advanced certifications in Clinical Research, Vaccinology, Project Management and Board Certified Medical Affairs Specialist (BCMAS) training from ACMA, USA.

Josemund Menezes

MBBS, BCMAS

Managing Director, Early-Stage Development (Asia Pacific)

Dr. Menezes has over 18 years of industry experience across MNC Pharma, biotech and CRO, spearheading global clinical development (Phase I to III executional strategy) in Oncology, Vaccines, and Immunology therapy areas. Prior to joining Zymeworks, Dr. Menezes held cross-functional team management and leadership roles at ASLAN Pharmaceuticals, Tessa Therapeutics, and Sanofi Pasteur. Dr. Menezes graduated from Maharashtra University of Health Sciences, India with a Bachelor of Medicine and Bachelor of Surgery (MBBS) degree, followed by advanced certifications in Clinical Research, Vaccinology, Project Management and Board Certified Medical Affairs Specialist (BCMAS) training from ACMA, USA.

MBBS, BCMAS

Josemund Menezes

MBBS, BCMAS

Managing Director, Early-Stage Development (Asia Pacific)

Dr. Menezes has over 18 years of industry experience across MNC Pharma, biotech and CRO, spearheading global clinical development (Phase I to III executional strategy) in Oncology, Vaccines, and Immunology therapy areas. Prior to joining Zymeworks, Dr. Menezes held cross-functional team management and leadership roles at ASLAN Pharmaceuticals, Tessa Therapeutics, and Sanofi Pasteur. Dr. Menezes graduated from Maharashtra University of Health Sciences, India with a Bachelor of Medicine and Bachelor of Surgery (MBBS) degree, followed by advanced certifications in Clinical Research, Vaccinology, Project Management and Board Certified Medical Affairs Specialist (BCMAS) training from ACMA, USA.

Board of Directors

Kenneth Galbraith

Chair & CEO

Mr. Galbraith has served as Zymeworks’ Chair & CEO since January 2022. Mr. Galbraith has over 35 years’ experience in biotechnology and venture capital having acted as an executive, director, investor as well as an advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors across North America and the UK in the growth of both private and public companies from an early-stage through regulatory approval and commercialization. Ken has worked with many biotechnology companies including: Macrogenics, AnorMED, Alder Pharmaceuticals, Celator Pharmaceuticals, Novadaq, Profound Medical, Fairhaven Pharmaceuticals, Tekmira, Angiotech, Aquinox, and Xenon Pharmaceuticals among others. Mr. Galbraith currently serves on the board of directors of Profound Medical and Kalium Health. He earned a Bachelor of Commerce (Honors) degree from the University of British Columbia in 1985.

Kenneth Galbraith

Chair & CEO

Mr. Galbraith has served as Zymeworks’ Chair & CEO since January 2022. Mr. Galbraith has over 35 years’ experience in biotechnology and venture capital having acted as an executive, director, investor as well as an advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors across North America and the UK in the growth of both private and public companies from an early-stage through regulatory approval and commercialization. Ken has worked with many biotechnology companies including: Macrogenics, AnorMED, Alder Pharmaceuticals, Celator Pharmaceuticals, Novadaq, Profound Medical, Fairhaven Pharmaceuticals, Tekmira, Angiotech, Aquinox, and Xenon Pharmaceuticals among others. Mr. Galbraith currently serves on the board of directors of Profound Medical and Kalium Health. He earned a Bachelor of Commerce (Honors) degree from the University of British Columbia in 1985.

Kenneth Galbraith

Chair & CEO

Mr. Galbraith has served as Zymeworks’ Chair & CEO since January 2022. Mr. Galbraith has over 35 years’ experience in biotechnology and venture capital having acted as an executive, director, investor as well as an advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors across North America and the UK in the growth of both private and public companies from an early-stage through regulatory approval and commercialization. Ken has worked with many biotechnology companies including: Macrogenics, AnorMED, Alder Pharmaceuticals, Celator Pharmaceuticals, Novadaq, Profound Medical, Fairhaven Pharmaceuticals, Tekmira, Angiotech, Aquinox, and Xenon Pharmaceuticals among others. Mr. Galbraith currently serves on the board of directors of Profound Medical and Kalium Health. He earned a Bachelor of Commerce (Honors) degree from the University of British Columbia in 1985.

Carlos Campoy

MBA

Director

Mr. Campoy has served as a member of our Board of Directors since June 2023. Mr. Campoy began his life sciences industry career at Eli Lilly and Company in 1996, serving in a variety of senior financial leadership roles in the U.S., Japan, Latin America and Europe over an 18-year span. As the Chief Financial Officer at Alder Biopharmaceuticals in Seattle, Washington, he led successful capital markets transactions to fund commercialization readiness for eptinezumab and played a key role in the eventual acquisition of Alder Biopharmaceuticals by Lundbeck in 2019 in a cash transaction in excess of $2 billion. He also previously held financial leadership positions at Allergan plc and, most recently, was the Chief Financial Officer at CytomX Therapeutics. He received an M.B.A. in Finance and Decision Information Systems from Indiana University and a Bachelor of Science degree in Management from Faculdade C.C. Administracao de Tupa (FACCAT) in Brazil.

Carlos Campoy

MBA

Director

Mr. Campoy has served as a member of our Board of Directors since June 2023. Mr. Campoy began his life sciences industry career at Eli Lilly and Company in 1996, serving in a variety of senior financial leadership roles in the U.S., Japan, Latin America and Europe over an 18-year span. As the Chief Financial Officer at Alder Biopharmaceuticals in Seattle, Washington, he led successful capital markets transactions to fund commercialization readiness for eptinezumab and played a key role in the eventual acquisition of Alder Biopharmaceuticals by Lundbeck in 2019 in a cash transaction in excess of $2 billion. He also previously held financial leadership positions at Allergan plc and, most recently, was the Chief Financial Officer at CytomX Therapeutics. He received an M.B.A. in Finance and Decision Information Systems from Indiana University and a Bachelor of Science degree in Management from Faculdade C.C. Administracao de Tupa (FACCAT) in Brazil.
MBA

Carlos Campoy

MBA

Director

Mr. Campoy has served as a member of our Board of Directors since June 2023. Mr. Campoy began his life sciences industry career at Eli Lilly and Company in 1996, serving in a variety of senior financial leadership roles in the U.S., Japan, Latin America and Europe over an 18-year span. As the Chief Financial Officer at Alder Biopharmaceuticals in Seattle, Washington, he led successful capital markets transactions to fund commercialization readiness for eptinezumab and played a key role in the eventual acquisition of Alder Biopharmaceuticals by Lundbeck in 2019 in a cash transaction in excess of $2 billion. He also previously held financial leadership positions at Allergan plc and, most recently, was the Chief Financial Officer at CytomX Therapeutics. He received an M.B.A. in Finance and Decision Information Systems from Indiana University and a Bachelor of Science degree in Management from Faculdade C.C. Administracao de Tupa (FACCAT) in Brazil.

Troy Cox

MBA

Director

Mr. Cox has served as a member of our Board of Directors since June 2019. Mr. Cox served as Chief Executive Officer of Foundation Medicine, Inc. from February 2017 through February 2019, as a member of Foundation Medicine’s board of directors from February 2017 until July 2018, and in the additional role of President of Foundation Medicine from February 2018 until July 2018. Prior to Foundation Medicine, Mr. Cox served as Senior Vice President, Sales & Marketing at Genentech, Inc. from February 2010 until February 2017. Before joining Genentech, Mr. Cox served as President of CNS operations at UCB S.A., with responsibility for developing and commercializing therapeutics for diseases primarily related to the central nervous system. Prior to UCB BioPharma, Mr. Cox held senior commercial leadership roles with Sanofi-Aventis and Schering-Plough. Mr. Cox serves on the board of directors of CM Life Sciences II Inc. and SOPHiA GENETICS SA. Mr. Cox received a B.B.A. in finance from the University of Kentucky and an M.B.A. from the University of Missouri.

Troy Cox

MBA

Director

Mr. Cox has served as a member of our Board of Directors since June 2019. Mr. Cox served as Chief Executive Officer of Foundation Medicine, Inc. from February 2017 through February 2019, as a member of Foundation Medicine’s board of directors from February 2017 until July 2018, and in the additional role of President of Foundation Medicine from February 2018 until July 2018. Prior to Foundation Medicine, Mr. Cox served as Senior Vice President, Sales & Marketing at Genentech, Inc. from February 2010 until February 2017. Before joining Genentech, Mr. Cox served as President of CNS operations at UCB S.A., with responsibility for developing and commercializing therapeutics for diseases primarily related to the central nervous system. Prior to UCB BioPharma, Mr. Cox held senior commercial leadership roles with Sanofi-Aventis and Schering-Plough. Mr. Cox serves on the board of directors of CM Life Sciences II Inc. and SOPHiA GENETICS SA. Mr. Cox received a B.B.A. in finance from the University of Kentucky and an M.B.A. from the University of Missouri.

MBA

Troy Cox

MBA

Director

Mr. Cox has served as a member of our Board of Directors since June 2019. Mr. Cox served as Chief Executive Officer of Foundation Medicine, Inc. from February 2017 through February 2019, as a member of Foundation Medicine’s board of directors from February 2017 until July 2018, and in the additional role of President of Foundation Medicine from February 2018 until July 2018. Prior to Foundation Medicine, Mr. Cox served as Senior Vice President, Sales & Marketing at Genentech, Inc. from February 2010 until February 2017. Before joining Genentech, Mr. Cox served as President of CNS operations at UCB S.A., with responsibility for developing and commercializing therapeutics for diseases primarily related to the central nervous system. Prior to UCB BioPharma, Mr. Cox held senior commercial leadership roles with Sanofi-Aventis and Schering-Plough. Mr. Cox serves on the board of directors of CM Life Sciences II Inc. and SOPHiA GENETICS SA. Mr. Cox received a B.B.A. in finance from the University of Kentucky and an M.B.A. from the University of Missouri.

Kenneth Hillan

MB, CHB

Director

Dr. Hillan has served as a member of our Board of Directors since February 2017. Dr. Hillan has served as Head of Therapeutics at 23andMe since February 2019. Dr. Hillan served on the board of directors of Achaogen, Inc., a public biopharmaceutical company, from October 2011 until April 2019. Dr. Hillan served as Achaogen’s President and President, R&D from January 2018 to October 2018, as its Chief Executive Officer from October 2011 until December 2017, and as its Chief Medical Officer from April 2011 to July 2014. Prior to joining Achaogen, Dr. Hillan worked at Genentech, Inc., a pharmaceutical company and a member of the Roche Group, from August 1994 to March 2011. Dr. Hillan held progressively senior roles at Genentech, most recently holding the position of Senior Vice President & Head of Roche Product Development, Asia Pacific from April 2010 to March 2011, and was responsible for numerous successful drug approvals and led the medical and scientific strategies for Genentech’s immunology, tissue growth and repair drug portfolio. Dr. Hillan has served on the board of directors of Sangamo Therapeutics, Inc. since September 2020, and served on the board of directors of Relypsa, Inc., a publicly traded biotechnology company that was acquired in September 2016 by Galencia AG for $1.5 billion, from June 2014 to September 2016. Dr. Hillan has an M.B. and a Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow in the United Kingdom. Dr. Hillan is a Fellow of the Royal College of Surgeons, and a Fellow of the Royal College of Pathologists.

Kenneth Hillan

MB, CHB

Director

Dr. Hillan has served as a member of our Board of Directors since February 2017. Dr. Hillan has served as Head of Therapeutics at 23andMe since February 2019. Dr. Hillan served on the board of directors of Achaogen, Inc., a public biopharmaceutical company, from October 2011 until April 2019. Dr. Hillan served as Achaogen’s President and President, R&D from January 2018 to October 2018, as its Chief Executive Officer from October 2011 until December 2017, and as its Chief Medical Officer from April 2011 to July 2014. Prior to joining Achaogen, Dr. Hillan worked at Genentech, Inc., a pharmaceutical company and a member of the Roche Group, from August 1994 to March 2011. Dr. Hillan held progressively senior roles at Genentech, most recently holding the position of Senior Vice President & Head of Roche Product Development, Asia Pacific from April 2010 to March 2011, and was responsible for numerous successful drug approvals and led the medical and scientific strategies for Genentech’s immunology, tissue growth and repair drug portfolio. Dr. Hillan has served on the board of directors of Sangamo Therapeutics, Inc. since September 2020, and served on the board of directors of Relypsa, Inc., a publicly traded biotechnology company that was acquired in September 2016 by Galencia AG for $1.5 billion, from June 2014 to September 2016. Dr. Hillan has an M.B. and a Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow in the United Kingdom. Dr. Hillan is a Fellow of the Royal College of Surgeons, and a Fellow of the Royal College of Pathologists.

MB, CHB

Kenneth Hillan

MB, CHB

Director

Dr. Hillan has served as a member of our Board of Directors since February 2017. Dr. Hillan has served as Head of Therapeutics at 23andMe since February 2019. Dr. Hillan served on the board of directors of Achaogen, Inc., a public biopharmaceutical company, from October 2011 until April 2019. Dr. Hillan served as Achaogen’s President and President, R&D from January 2018 to October 2018, as its Chief Executive Officer from October 2011 until December 2017, and as its Chief Medical Officer from April 2011 to July 2014. Prior to joining Achaogen, Dr. Hillan worked at Genentech, Inc., a pharmaceutical company and a member of the Roche Group, from August 1994 to March 2011. Dr. Hillan held progressively senior roles at Genentech, most recently holding the position of Senior Vice President & Head of Roche Product Development, Asia Pacific from April 2010 to March 2011, and was responsible for numerous successful drug approvals and led the medical and scientific strategies for Genentech’s immunology, tissue growth and repair drug portfolio. Dr. Hillan has served on the board of directors of Sangamo Therapeutics, Inc. since September 2020, and served on the board of directors of Relypsa, Inc., a publicly traded biotechnology company that was acquired in September 2016 by Galencia AG for $1.5 billion, from June 2014 to September 2016. Dr. Hillan has an M.B. and a Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow in the United Kingdom. Dr. Hillan is a Fellow of the Royal College of Surgeons, and a Fellow of the Royal College of Pathologists.

Sue Mahony

PhD MBA

Director

Dr. Mahony has served as a member of our Board of Directors since June 2019. Dr. Mahony is an executive with over 30 years of experience in pharmaceutical and life sciences companies. Dr. Mahony served as Senior Vice President of Eli Lilly and Company and President of Lilly Oncology from February 2011 until August 2018. She joined Lilly in 2000, holding senior leadership positions in product development, marketing, human resources, and general management. Prior to joining Lilly, Dr. Mahony served in sales and marketing roles in Europe for over a decade for Schering-Plough, Amgen, and Bristol-Myers Squibb. Dr. Mahony has served on the board of directors of Assembly Biosciences, Inc. since December 2017, on the board of directors for Vifor Pharma since May 2019, and on the board of directors of Horizon Therapeutics Public Limited Company since August 2019. Dr. Mahony received a B.Sc. and a Ph.D. from Aston University and an M.B.A. from London Business School.

Sue Mahony

PhD MBA

Director

Dr. Mahony has served as a member of our Board of Directors since June 2019. Dr. Mahony is an executive with over 30 years of experience in pharmaceutical and life sciences companies. Dr. Mahony served as Senior Vice President of Eli Lilly and Company and President of Lilly Oncology from February 2011 until August 2018. She joined Lilly in 2000, holding senior leadership positions in product development, marketing, human resources, and general management. Prior to joining Lilly, Dr. Mahony served in sales and marketing roles in Europe for over a decade for Schering-Plough, Amgen, and Bristol-Myers Squibb. Dr. Mahony has served on the board of directors of Assembly Biosciences, Inc. since December 2017, on the board of directors for Vifor Pharma since May 2019, and on the board of directors of Horizon Therapeutics Public Limited Company since August 2019. Dr. Mahony received a B.Sc. and a Ph.D. from Aston University and an M.B.A. from London Business School.

PhD MBA

Sue Mahony

PhD MBA

Director

Dr. Mahony has served as a member of our Board of Directors since June 2019. Dr. Mahony is an executive with over 30 years of experience in pharmaceutical and life sciences companies. Dr. Mahony served as Senior Vice President of Eli Lilly and Company and President of Lilly Oncology from February 2011 until August 2018. She joined Lilly in 2000, holding senior leadership positions in product development, marketing, human resources, and general management. Prior to joining Lilly, Dr. Mahony served in sales and marketing roles in Europe for over a decade for Schering-Plough, Amgen, and Bristol-Myers Squibb. Dr. Mahony has served on the board of directors of Assembly Biosciences, Inc. since December 2017, on the board of directors for Vifor Pharma since May 2019, and on the board of directors of Horizon Therapeutics Public Limited Company since August 2019. Dr. Mahony received a B.Sc. and a Ph.D. from Aston University and an M.B.A. from London Business School.

Derek Miller

MBA

Director

Mr. Miller has served as a member of our Board of Directors since April 2023. Mr. Miller has been a leader in the biotechnology and pharmaceutical sector for more than 25 years with experience in corporate development, business development and global commercial strategy. He is an independent commercial and business development consultant for a clinical-stage oncology company and a late-stage ultra-rare disease company, and currently serves as Chief Executive Officer of a cell and gene therapy imaging startup venture, spun out from the University of Pennsylvania. Previously, he served as Chief Business Officer of Aro Biotherapeutics, a spinout of Janssen Pharmaceuticals, leading numerous strategic and operational initiatives including a transformative collaboration with Ionis with potential revenues for up to $1.4 billion. Mr. Miller also previously served as Chief Business Officer of Celator Pharmaceuticals where he led the development of their pipeline and business development strategy, resulting in its acquisition by Jazz Pharmaceuticals in 2016 for cash proceeds of approximately $1.5 billion. Prior to Celator Pharmaceuticals, Mr. Miller held a variety of marketing, sales and market access roles with Genentech, Centocor and GSK. Mr. Miller is a member of the Board of Trustees for the Eastern Pennsylvania Chapter of the Leukemia and Lymphoma Society and serves as a mentor for the Villanova School of Business. He received an M.B.A. from Villanova University and Bachelor of Arts and Science degree from the University of Delaware.

Derek Miller

MBA

Director

Mr. Miller has served as a member of our Board of Directors since April 2023. Mr. Miller has been a leader in the biotechnology and pharmaceutical sector for more than 25 years with experience in corporate development, business development and global commercial strategy. He is an independent commercial and business development consultant for a clinical-stage oncology company and a late-stage ultra-rare disease company, and currently serves as Chief Executive Officer of a cell and gene therapy imaging startup venture, spun out from the University of Pennsylvania. Previously, he served as Chief Business Officer of Aro Biotherapeutics, a spinout of Janssen Pharmaceuticals, leading numerous strategic and operational initiatives including a transformative collaboration with Ionis with potential revenues for up to $1.4 billion. Mr. Miller also previously served as Chief Business Officer of Celator Pharmaceuticals where he led the development of their pipeline and business development strategy, resulting in its acquisition by Jazz Pharmaceuticals in 2016 for cash proceeds of approximately $1.5 billion. Prior to Celator Pharmaceuticals, Mr. Miller held a variety of marketing, sales and market access roles with Genentech, Centocor and GSK. Mr. Miller is a member of the Board of Trustees for the Eastern Pennsylvania Chapter of the Leukemia and Lymphoma Society and serves as a mentor for the Villanova School of Business. He received an M.B.A. from Villanova University and Bachelor of Arts and Science degree from the University of Delaware.

MBA

Derek Miller

MBA

Director

Mr. Miller has served as a member of our Board of Directors since April 2023. Mr. Miller has been a leader in the biotechnology and pharmaceutical sector for more than 25 years with experience in corporate development, business development and global commercial strategy. He is an independent commercial and business development consultant for a clinical-stage oncology company and a late-stage ultra-rare disease company, and currently serves as Chief Executive Officer of a cell and gene therapy imaging startup venture, spun out from the University of Pennsylvania. Previously, he served as Chief Business Officer of Aro Biotherapeutics, a spinout of Janssen Pharmaceuticals, leading numerous strategic and operational initiatives including a transformative collaboration with Ionis with potential revenues for up to $1.4 billion. Mr. Miller also previously served as Chief Business Officer of Celator Pharmaceuticals where he led the development of their pipeline and business development strategy, resulting in its acquisition by Jazz Pharmaceuticals in 2016 for cash proceeds of approximately $1.5 billion. Prior to Celator Pharmaceuticals, Mr. Miller held a variety of marketing, sales and market access roles with Genentech, Centocor and GSK. Mr. Miller is a member of the Board of Trustees for the Eastern Pennsylvania Chapter of the Leukemia and Lymphoma Society and serves as a mentor for the Villanova School of Business. He received an M.B.A. from Villanova University and Bachelor of Arts and Science degree from the University of Delaware.

Kelvin Neu

MD

Director

Dr. Neu has served as a member of our Board of Directors since March 2020. Dr. Neu was a Partner at Baker Bros. Advisors LP, a registered investment adviser, from April 2004 until January 2021. Dr. Neu previously served on the board of directors of IGM Biosciences, Prelude Therapeutics, Idera Pharmaceuticals, Aquinox Pharmaceuticals and XOMA Corporation. Dr. Neu holds an M.D. from the Harvard Medical School-MIT Health Sciences and Technology program, and spent three years in the Immunology Ph.D. program at Stanford University as a Howard Hughes Medical Institute Fellow. Dr. Neu holds an A.B. (summa cum laude) from Princeton University, where he was awarded the Khoury Prize for graduating first in his department of Molecular Biology. Prior to attending Princeton, Dr. Neu served for two and a half years in the military of his native Singapore.

Kelvin Neu

MD

Director

Dr. Neu has served as a member of our Board of Directors since March 2020. Dr. Neu was a Partner at Baker Bros. Advisors LP, a registered investment adviser, from April 2004 until January 2021. Dr. Neu previously served on the board of directors of IGM Biosciences, Prelude Therapeutics, Idera Pharmaceuticals, Aquinox Pharmaceuticals and XOMA Corporation. Dr. Neu holds an M.D. from the Harvard Medical School-MIT Health Sciences and Technology program, and spent three years in the Immunology Ph.D. program at Stanford University as a Howard Hughes Medical Institute Fellow. Dr. Neu holds an A.B. (summa cum laude) from Princeton University, where he was awarded the Khoury Prize for graduating first in his department of Molecular Biology. Prior to attending Princeton, Dr. Neu served for two and a half years in the military of his native Singapore.

MD

Kelvin Neu

MD

Director

Dr. Neu has served as a member of our Board of Directors since March 2020. Dr. Neu was a Partner at Baker Bros. Advisors LP, a registered investment adviser, from April 2004 until January 2021. Dr. Neu previously served on the board of directors of IGM Biosciences, Prelude Therapeutics, Idera Pharmaceuticals, Aquinox Pharmaceuticals and XOMA Corporation. Dr. Neu holds an M.D. from the Harvard Medical School-MIT Health Sciences and Technology program, and spent three years in the Immunology Ph.D. program at Stanford University as a Howard Hughes Medical Institute Fellow. Dr. Neu holds an A.B. (summa cum laude) from Princeton University, where he was awarded the Khoury Prize for graduating first in his department of Molecular Biology. Prior to attending Princeton, Dr. Neu served for two and a half years in the military of his native Singapore.

Hollings C Renton

MBA

Director

Mr. Renton has served as a member of our Board of Directors since February 2017. Mr. Renton served as Chief Executive Officer and President of Onyx Pharmaceuticals, Inc. from March 1993 to March 2008 and was the chair of the board of directors of Onyx from June 2000 to March 2008. Onyx was acquired by Amgen Inc. in 2013 for $10.4 billion. Before joining Onyx, Mr. Renton was the President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company, from December 1991 to December 1993. Mr. Renton served in a variety of executive roles at Cetus Corporation from 1983, including as President from 1990 to 1991, Chief Operating Officer from 1987 to 1990 and Chief Financial Officer from 1983 to 1987, prior to its acquisition by Chiron in 1991. Mr. Renton has served on the board of directors of AnaptysBio, Inc. since June 2015. Previously, Mr. Renton served on the boards of four other biopharmaceutical companies: Portola Pharmaceuticals Inc., where he had also been board chair (March 2010 to July 2020), KYTHERA Biopharmaceuticals, Inc. (December 2014 to October 2015), Affymax, Inc. (June 2009 to November 2014) and Rigel Pharmaceuticals, Inc. (January 2004 to March 2014). Mr. Renton also previously served on the board of Cepheid Inc., a molecular diagnostics company, from March 2000 to November 2016. Mr. Renton received his M.B.A. from the University of Michigan and his B.S. in Mathematics from Colorado State University.

Hollings C Renton

MBA

Director

Mr. Renton has served as a member of our Board of Directors since February 2017. Mr. Renton served as Chief Executive Officer and President of Onyx Pharmaceuticals, Inc. from March 1993 to March 2008 and was the chair of the board of directors of Onyx from June 2000 to March 2008. Onyx was acquired by Amgen Inc. in 2013 for $10.4 billion. Before joining Onyx, Mr. Renton was the President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company, from December 1991 to December 1993. Mr. Renton served in a variety of executive roles at Cetus Corporation from 1983, including as President from 1990 to 1991, Chief Operating Officer from 1987 to 1990 and Chief Financial Officer from 1983 to 1987, prior to its acquisition by Chiron in 1991. Mr. Renton has served on the board of directors of AnaptysBio, Inc. since June 2015. Previously, Mr. Renton served on the boards of four other biopharmaceutical companies: Portola Pharmaceuticals Inc., where he had also been board chair (March 2010 to July 2020), KYTHERA Biopharmaceuticals, Inc. (December 2014 to October 2015), Affymax, Inc. (June 2009 to November 2014) and Rigel Pharmaceuticals, Inc. (January 2004 to March 2014). Mr. Renton also previously served on the board of Cepheid Inc., a molecular diagnostics company, from March 2000 to November 2016. Mr. Renton received his M.B.A. from the University of Michigan and his B.S. in Mathematics from Colorado State University.

MBA

Hollings C Renton

MBA

Director

Mr. Renton has served as a member of our Board of Directors since February 2017. Mr. Renton served as Chief Executive Officer and President of Onyx Pharmaceuticals, Inc. from March 1993 to March 2008 and was the chair of the board of directors of Onyx from June 2000 to March 2008. Onyx was acquired by Amgen Inc. in 2013 for $10.4 billion. Before joining Onyx, Mr. Renton was the President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company, from December 1991 to December 1993. Mr. Renton served in a variety of executive roles at Cetus Corporation from 1983, including as President from 1990 to 1991, Chief Operating Officer from 1987 to 1990 and Chief Financial Officer from 1983 to 1987, prior to its acquisition by Chiron in 1991. Mr. Renton has served on the board of directors of AnaptysBio, Inc. since June 2015. Previously, Mr. Renton served on the boards of four other biopharmaceutical companies: Portola Pharmaceuticals Inc., where he had also been board chair (March 2010 to July 2020), KYTHERA Biopharmaceuticals, Inc. (December 2014 to October 2015), Affymax, Inc. (June 2009 to November 2014) and Rigel Pharmaceuticals, Inc. (January 2004 to March 2014). Mr. Renton also previously served on the board of Cepheid Inc., a molecular diagnostics company, from March 2000 to November 2016. Mr. Renton received his M.B.A. from the University of Michigan and his B.S. in Mathematics from Colorado State University.

Lota Zoth

CPA

Lead Independent Director

Ms. Zoth served as the Chair of our Board of Directors from September 2019-January 2022 and as a member of our Board of Directors since November 2016. Ms. Zoth is a Certified Public Accountant and has served as Chief Financial Officer, Chief Accounting Officer and Controller for various publicly traded companies, including MedImmune, Inc. and PSINet, Inc., and as a financial executive in various roles at Sodexho Marriott, Marriott International, Pepsi-Cola International and PepsiCo. Ms. Zoth began her career as an auditor with Ernst & Young. Ms. Zoth serves on the boards and audit committees of Nasdaq-listed biopharmaceutical companies Inovio Pharmaceuticals, Inc., Lumos Pharma, Inc. and 89Bio, Inc. Previously, Ms. Zoth served on the boards of six other biopharmaceutical companies (Aeras, Circassia Pharmaceuticals, plc, Hyperion Therapeutics, Inc., Ikaria, Inc. Orexigen Therapeutics, Inc., and Spark Therapeutics, Inc.).

Lota Zoth

CPA

Lead Independent Director

Ms. Zoth served as the Chair of our Board of Directors from September 2019-January 2022 and as a member of our Board of Directors since November 2016. Ms. Zoth is a Certified Public Accountant and has served as Chief Financial Officer, Chief Accounting Officer and Controller for various publicly traded companies, including MedImmune, Inc. and PSINet, Inc., and as a financial executive in various roles at Sodexho Marriott, Marriott International, Pepsi-Cola International and PepsiCo. Ms. Zoth began her career as an auditor with Ernst & Young. Ms. Zoth serves on the boards and audit committees of Nasdaq-listed biopharmaceutical companies Inovio Pharmaceuticals, Inc., Lumos Pharma, Inc. and 89Bio, Inc. Previously, Ms. Zoth served on the boards of six other biopharmaceutical companies (Aeras, Circassia Pharmaceuticals, plc, Hyperion Therapeutics, Inc., Ikaria, Inc. Orexigen Therapeutics, Inc., and Spark Therapeutics, Inc.).

CPA

Lota Zoth

CPA

Lead Independent Director

Ms. Zoth served as the Chair of our Board of Directors from September 2019-January 2022 and as a member of our Board of Directors since November 2016. Ms. Zoth is a Certified Public Accountant and has served as Chief Financial Officer, Chief Accounting Officer and Controller for various publicly traded companies, including MedImmune, Inc. and PSINet, Inc., and as a financial executive in various roles at Sodexho Marriott, Marriott International, Pepsi-Cola International and PepsiCo. Ms. Zoth began her career as an auditor with Ernst & Young. Ms. Zoth serves on the boards and audit committees of Nasdaq-listed biopharmaceutical companies Inovio Pharmaceuticals, Inc., Lumos Pharma, Inc. and 89Bio, Inc. Previously, Ms. Zoth served on the boards of six other biopharmaceutical companies (Aeras, Circassia Pharmaceuticals, plc, Hyperion Therapeutics, Inc., Ikaria, Inc. Orexigen Therapeutics, Inc., and Spark Therapeutics, Inc.).